Clinical presentations and therapy of polysubstance dependence in patients with schizophrenia

Ivanets N.N.; Vinnikova M.A.; Ezhkova E.V.; Titkov M.S.; Bulatova R.A.

doi:https://doi.org/10.17116/jnevro202112104163

Ivanets N.N.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-0013-5031

Vinnikova M.A.

Sechenov First Moscow State Medical University (Sechenov University);
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare

ORCID: 0000-0003-3289-8786

Ezhkova E.V.

Moscow Research and Practical Center on Addictions

Titkov M.S.

European Medicine Center

Bulatova R.A.

Moscow Research and Practical Center on Addictions

Clinical presentations and therapy of polysubstance dependence in patients with schizophrenia

Authors:

Ivanets N.N., Vinnikova M.A., Ezhkova E.V., Titkov M.S., Bulatova R.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4): 63‑69

DOI: 10.17116/jnevro202112104163

Read: 3514 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ivanets NN, Vinnikova MA, Ezhkova EV, Titkov MS, Bulatova RA. Clinical presentations and therapy of polysubstance dependence in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4):63‑69. (In Russ.)
https://doi.org/10.17116/jnevro202112104163

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

BACKGROUND

The article presents the results of a clinical therapeutic and follow-up study of patients with a ‘dual diagnosis’ (polysubstance dependence comorbid with schizophrenia: paranoid schizophrenia or schizotypal disorder).

OBJECTIVE

To study clinical/dynamic changes of polysubstance dependence in patients with schizophrenia (paranoid schizophrenia, schizotypal disorder) and to evaluate the duration and quality of therapeutic remissions.

MATERIAL AND METHODS

Two hundred and sixty-six male patients, including 176 patients with dependence syndrome and 90 patients with both dependence syndrome and schizophrenia, were studied.

RESULTS

Patients with the ‘dual diagnosis’ are characterized by early social maladjustment, earlier social deformation, lack of social skills and preference for a lonely lifestyle. The clinical and dynamic characteristics of dependence syndrome in patients with ‘dual diagnosis’ include older age of the first use of a psychoactive substance (PS), preference of alcohol as the first PS, experiment as the most frequent motivation for using PS (due to thought disorder), and the treatment of psychopathological disorders (PS like medicine) with a chaotic pattern being the most common in the use, a tendency to hospitalism.

CONCLUSION

The success of the treatment of patients with ‘dual diagnosis’ is possible by combining the therapy of endogenous disease and polysubstance dependence.

Keywords:

schizophrenia

drug addiction

craving

dual diagnosis

remission

follow-up

survival curve

atypical antipsychotics

Authors:

Ivanets N.N.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-0013-5031

Vinnikova M.A.

Sechenov First Moscow State Medical University (Sechenov University);
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare

ORCID: 0000-0003-3289-8786

Ezhkova E.V.

Moscow Research and Practical Center on Addictions

Titkov M.S.

European Medicine Center

Bulatova R.A.

Moscow Research and Practical Center on Addictions

Received:

10.04.2020

Accepted:

21.04.2020

Close metadata

References:

Bokhan NA, Semke VYa. Komorbidnost’ v narkologii. Tomsk: Izdatel’stvo Tomskogo universiteta; 2009. (In Russ.).
Scheller-Gilkey G, Moynes K, Cooper I, et al. Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr Res. 2004;69(2-3):167-174. https://doi.org/10.1016/s0920-9964(03)00188-9
Green AI, Tohen MF, Hamer RM, et al. First-episode schizophrenia — related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;23(2-3):125-135. https://doi.org/10.1016/j.schres.2003.08.001
Moggi F. Epidemiology, etiology and treatment of patients with psychosis and co-morbid substance use disorder. Ther Umsch. 2018;75(1):37-43. https://doi.org/10.1024/0040-5930/a000964
Eric AE, Donald WB. Epidemiology and risk factors Infuencing Schizophrenia. In: Schulz SC, Green MF, Nelson KJ, eds. Schizophrenia and Psychotic Spectrum Disorders. Oxford University Press; 2016. https://doi.org/10.1093/med/9780199378067.003.0003
Swendsen J, Conway KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction. 2010;105(6): 1117-1128. https://doi.org/10.1111/j.1360-0443.2010.02902.x
Bhalla IP, Stefanovics EA, Rosenheck RA. Clinical Epidemiology of Single versus Multiple Substance Use Disorders: Polysubstance Use Disorder. Med Care. 2017;55:24-32. https://doi.org/10.1097/mlr.0000000000000731
Alekseeva DN, Bakuleva NI. Clinical aspects of schizophrenia, comorbid with drug addiction. Young Scientist. 2017;(15):146-149. (In Russ.).
Chiappelli J, Chen S, Hackman A. Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population. Schizophr Res. 2018;194:23-31. https://doi.org/10.1016/j.schres.2017.05.004
Bramness J, Gundersen O, Guterstam J. Amphetamine-induced psychosis — a separate diagnostic entity or primary psychosis triggered in the vulnerable. BMC Psychiatry. 2012;12:221. https://doi.org/10.1186/1471-244x-12-221
Green A, Khokhar J. Addiction and schizophrenia: A translational perspective. Schizophr Res. 2018;194:1-3. https://doi.org/10.1016/j.schres.2017.10.008
Gofman AG, Shlemina IV, Loshakov ES, Malkov KD. Schizophrenia (schizotypal disorder) comorbid with alcoholism. Nezavisimyj psikhiatricheskij zhurnal. 2001;(1):21-25. (In Russ.).
Malkov KD. Features of the syndrome dynamics of schizotypic disorder combined with alcoholism. Voprosy narkologii. 1999;(4):23-29. (In Russ.).
Agaev MM. Features of the clinical picture of patients with schizotypic personality disorders who used opium drugs. Narkologiya. 2007;(1):71-72. (In Russ.).
Kerner B. Comorbid substance use disorders in schizophrenia: a latent class approach. Psychiatry Res. 2015;225(3):395-401. https://doi.org/10.1016/j.psychres.2014.12.006
Ipser J, Wilson D, Akindipe T, et al. Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev. 2015;(1): CD007505. https://doi.org/10.1002/14651858.CD007505.pub2
Gouzoulis-Mayfrank E, König S, Koebke S, et al. Dual diagnosis psychosis and substance use disorders: theoretical foundations and treatment. Dtsch Arztebl Int. 2015;112(41):683-691. https://doi.org/10.3238/arztebl.2015.0683
Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid chizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin. 2006;22(7):1277-1285. https://doi.org/10.1185/030079906x112561
Anne-Noël S. Can antipsychotic treatment contribute to drug addiction in schizophrenia? Schizophr Res. 2014;3(52):9-16. https://doi.org/10.1016/j.pnpbp.2013.06.008
Filippova NV, Barylnik YuB, Pimenova MO, Nelovko TV. Schizophrenia and alcohol dependence: comorbidity of clinical manifestations and therapeutic approaches. Narcology. 2019;7:92-97. (In Russ.).
Coffin P, Santos G, Das M, et al. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013;108(4):751-761. https://doi.org/10.1111/add.12073
Pinkofsky HB, Hahn AM, Campbell FA, et al. Reduction of opioid — withdrawal symptoms with quetiapine. J Clin Psychiatry. 2005;66(10):1285-1288. https://doi.org/10.4088/jcp.v66n1011
Huskisson ES. Assesment for clinical trials. Clin Rheum Dis. 1976;2:37-49.
Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subs Abuse Treat. 2002;23(4):273-283. https://doi.org/10.1016/s0740-5472(02)00275-1
Vinnikova MA. Clinical and diagnostic criteria for pathological drug addiction. Voprosy narkologii. 2001;(2):20-26. (In Russ.).
Morosini PL, Magliano L, Brambilla, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323-329.
Mosolov SN, Potapov AV, Shafarenko AA, et al. Validation of standardized clinical and functional criteria for remission in schizophrenia. Social and Clinical Psychiatry. 2011;(3):36-42. (In Russ.).
Ivanets NN, Vinnikova MA, Ezhkova EV, et al. Aripiprazole and quetiapine in the treatment of patients with «dual diagnosis» of schizophrenia and drug addiction. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9): 52-61. (In Russ.). https://doi.org/10.17116/jnevro201911909152